Merck & Co Inc - Company Profile
Powered by 
All the data and insights you need on Merck & Co Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date Merck & Co Inc Strategy Report
- Understand Merck & Co Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Related keylists
View moreMerck & Co Inc (Merck) is a biopharmaceutical company focused on the discovery, development, manufacturing and marketing of prescription medicines, biologic therapies, vaccines, and animal health products. It offers prescription products for therapy areas related to cardiovascular, cancer, immune disorders, infectious, respiratory, and diabetes. The company provides animal health products such as vaccines, poultry products, livestock products and aquaculture products. Merck sells medicines to drug wholesalers, retailers, hospitals, government agencies and managed health care providers; and animal health products to veterinarians, distributors and animal producers. The company and its subsidiaries operate in the Americas, Europe, the Middle East, Africa, Asia Pacific, and Latin America. Merck is known as MSD outside the US and Canada and is headquartered in Kenilworth, New Jersey, the US.
Headquarters
United States of America
Address
2000 Galloping Hill Road, Kenilworth, New Jersey, 07033
Website
www.merck.com
Telephone
1 908 7404000
No of Employees
69,000
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
MRK (NYSE)
Revenue (2022)
$59.3B
21.7%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
11.3%
(2022 vs 2021)
Market Cap*
$263.2B
Net Profit Margin (2022)
XYZ
-8.6%
(2022 vs 2021)
* As of and is in US$
Merck & Co Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| - | - |
| Vaccine: | Zetia |
| Influenza Virus Vaccine | Vytorin |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Contracts/Agreements | In December, the company entered a clinical collaboration with HiberCell, Inc. to evaluate HC-7366, HiberCell’s first-in-class, potent and selective activator of the general control nonderepressible 2 (GCN2) kinase for the treatment of clear cell renal cell carcinoma. |
| 2023 | Contracts/Agreements | In November, the company announced a collaboration with Acclinate to help increase participation by members of the Black/African American community in Merck's oncology clinical studies. |
| 2023 | Contracts/Agreements | In November, the company entered into an agreement to acquire Caraway Therapeutics. |
Competitor Comparison
| Key Parameters | Merck & Co Inc | Pfizer Inc | Johnson & Johnson | AbbVie Inc | Novartis AG |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | Switzerland |
| City | Kenilworth | New York | New Brunswick | North Chicago | Basel |
| State/Province | New Jersey | New York | New Jersey | Illinois | - |
| No. of Employees | 69,000 | 83,000 | 152,700 | 50,000 | 103,000 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Robert M. Davis | Chairman; Chief Executive Officer; President | Executive Board | 2022 | 56 |
| Caroline Litchfield | Chief Financial Officer; Executive Vice President | Senior Management | 2021 | 54 |
| Michael Klobuchar | Chief Strategy Officer; Executive Vice President | Senior Management | 2021 | 47 |
| Eliav Barr | Chief Medical Officer; Head - Global Clinical Development | Senior Management | 2022 | - |
| Steven C. Mizell | Chief Human Resources Officer; Executive Vice President | Senior Management | 2016 | 62 |
| Non Dignissim Eros | Proin vel | Convallis | 2023 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2023 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2023 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward